Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire Vaudois
Objectives:
Primary
\- To evaluate the equivalence of the time on active surveillance before an active treatment between group Epstein + and the expanded active surveillance group (Epstein -)
Secondary
* To evaluate the role of diffusion-weighted MRI (DW-MRI) in the initial diagnosis and the follow-up of patients under active surveillance
* To evaluate the role of BCAR-1 to predict the clinical outcome of localized prostate cancer
* To evaluate the proportion of patients who discontinued active surveillance
* To evaluate the mortality at 10, 15 and 20 years from the inclusion in the study
* To evaluate the time to radical treatment
* To evaluate the time to metastatic disease
* To evaluate patients quality of life
Age
18–75
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Localized adenocarcinoma of the prostate with a Gleason score of 3+3 (group I patients) or 3+4 (group II patients)
Percentage of tumor biopsy invasion \<50% and/or with a size of maximum 8 mm
With a number of positive tumor biopsies ≤3 (group I patients) or ≤ 5 (group II patients)
TNM stage T1-2a N0 M0 (group I patients); TNM stage T1-2c N0 M0 (group II patients)
PSA level at diagnosis \< 10 ng/ml for group I patients; \< 15 ng/ml for group II patients
Tumor volume negative (group I patients); positive (group II patients)
Absence of extra-capsular extension
Life expectancy \> 10 years
Signed informed consent
Patient has elected active surveillance as preferred management plan for the prostate cancer
You may not be if
Previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery or chemotherapy)
